Li YL, Chen EG, Ren BB. Umbilical cord-derived mesenchymal stromal cells: Promising therapy for heart failure. World J Cardiol 2025; 17(1): 101153 [PMID: PMC11755126 DOI: 10.4330/wjc.v17.i1.101153]
Corresponding Author of This Article
Bing-Bing Ren, PhD, Associate Professor, Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. renbb@ustc.edu.cn
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jan 26, 2025; 17(1): 101153 Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.101153
Umbilical cord-derived mesenchymal stromal cells: Promising therapy for heart failure
Ya-Lun Li, En-Guo Chen, Bing-Bing Ren
Ya-Lun Li, En-Guo Chen, Bing-Bing Ren, Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Ya-Lun Li, Medical College, Zhejiang University, Hangzhou 310063, Zhejiang Province, China
Co-corresponding authors: En-Guo Chen and Bing-Bing Ren.
Author contributions: Li YL and Ren BB designed the overall concept and outline of the manuscript; Chen EG contributed to the discussion and design of the manuscript; Li YL, Chen EG, and Ren BB contributed to the writing, and editing of the manuscript; Chen EG and Ren BB designed and revised the manuscript, and supervised the whole process of the project, they are the co-corresponding authors of this manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing-Bing Ren, PhD, Associate Professor, Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. renbb@ustc.edu.cn
Received: September 5, 2024 Revised: November 6, 2024 Accepted: December 2, 2024 Published online: January 26, 2025 Processing time: 137 Days and 20.8 Hours
Abstract
Heart failure (HF) is a complex syndrome characterized by the reduced capacity of the heart to adequately fill or eject blood. Currently, HF remains a leading cause of morbidity and mortality worldwide, imposing a substantial burden on global healthcare systems. Recent advancements have highlighted the therapeutic potential of mesenchymal stromal cells (MSCs) in managing HF. Notably, umbilical cord-derived MSCs (UC-MSCs) have demonstrated superior clinical potential compared to traditional bone marrow-derived MSCs; this is evident in their non-invasive collection process, higher proliferation efficacy, and lower immunogenicity and tumorigenicity, as substantiated by preclinical studies. Although the feasibility and safety of UC-MSCs have been tested in animal models, the application of UC-MSCs in HF treatment remains challenged by issues such as inaccurate targeted migration and low survival rates of UC-MSCs. Therefore, further research and clinical trials are imperative to advance the clinical application of UC-MSCs.
Core Tip: There has been increased emphasis on the efficacy and potential of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for reversing cardiac remodeling in heart failure. UC-MSCs exhibit low immunogenicity and tumorigenicity, with a painless, non-invasive collection process. Compared to bone marrow-derived mesenchymal stromal cells, UC-MSCs exhibit superior proliferation, migration, immunosuppressive effects, and paracrine activity. However, their efficacy largely depends on the primitive source and extraction/delivery methods. Therefore, optimizing extraction/delivery techniques and conducting rigorous clinical trials are essential for further clinical implementation of UC-MSCs in heart failure patients.
